Gisondi, P.; Geat, D.; Maurelli, M.; Degli Esposti, L.; Bellinato, F.; Girolomoni, G.
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines 2022, 10, 646.
https://doi.org/10.3390/vaccines10050646
AMA Style
Gisondi P, Geat D, Maurelli M, Degli Esposti L, Bellinato F, Girolomoni G.
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines. 2022; 10(5):646.
https://doi.org/10.3390/vaccines10050646
Chicago/Turabian Style
Gisondi, Paolo, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato, and Giampiero Girolomoni.
2022. "Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease" Vaccines 10, no. 5: 646.
https://doi.org/10.3390/vaccines10050646
APA Style
Gisondi, P., Geat, D., Maurelli, M., Degli Esposti, L., Bellinato, F., & Girolomoni, G.
(2022). Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines, 10(5), 646.
https://doi.org/10.3390/vaccines10050646